Holen Sie sich die Stockscreener-App
1.0798
0.01%
0.0098
Schlusskurs vom Vortag:
$1.07
Offen:
$1.07
24-Stunden-Volumen:
36,589
Relative Volume:
0.28
Marktkapitalisierung:
$4.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.04M
KGV:
-0.2466
EPS:
-4.3784
Netto-Cashflow:
$-6.17M
1W Leistung:
+0.95%
1M Leistung:
+12.63%
6M Leistung:
-57.54%
1J Leistung:
-81.29%
1-Tages-Spanne:
$1.07
$1.0999
1-Wochen-Bereich:
$1.0257
$1.16
52-Wochen-Spanne:
$0.84
$8.22
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA
Compare ALZN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.075 | 4.07M | 0 | -7.04M | -6.17M | -4.3784 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.53 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.51 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.37 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
ALZN Stock Price, Quote & Chart | ALZAMEND NEURO INC (NASDAQ:ALZN) - ChartMill
Alzamend Neuro (ALZN) price target decreased by 10.71% to 25.50 - MSN
Alzamend (ALZN) Stock Swing Trade Setup (On the Radar) 2026-04-20Sector Rotation - Cổng thông tin điện tử Tỉnh Sơn La
Alzamend Neuro, Inc. 8-K Filing Details, NASDAQ Listing, and Corporate Information (April 17, 2026) - Minichart
Alzamend Neuro Shareholders Approve Governance and Capital Measures - TipRanks
Shareholders of Alzamend Neuro (ALZN) approve board slate, plans and reverse split - Stock Titan
Director Milton Ault adds Alzamend Neuro (ALZN) shares in open-market buy - Stock Titan
CEO Moves: How sensitive is Alzamend Neuro Inc to inflationEarnings Overview Report & Smart Investment Allocation Tips - baoquankhu1.vn
Form PRE 14AOther preliminary proxy statements - ADVFN
Can Alzamend Neuro Inc disrupt its industryEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Aug Sectors: What is the dividend yield of Alzamend Neuro IncQuarterly Profit Review & Long-Term Safe Return Strategies - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - Sahm
In a 6-person study, new lithium therapy disturbed less brain chemistry - Stock Titan
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - MSN
Hedge Fund Bets: Can Alzamend Neuro Inc disrupt its industryChart Signals & Consistent Income Trade Recommendations - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Alzamend’s AL001 meets bioequivalence in phase 2 brain trial By Investing.com - Investing.com Australia
Alzamend Neuro in Freefall: A 22% Plunge Shatters $1.93 as Panic Sets In - Bitget
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - Investing News Network
Alzamend’s AL001 meets bioequivalence in phase 2 brain trial - Investing.com
Across 26 brain regions, Alzamend’s lithium drug showed higher levels - Stock Titan
Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency - The Globe and Mail
Alzamend Neuro, Inc. Receives Nasdaq Delisting Notice: SEC Form 8-K Filing March 2026 - Minichart
Alzamend Neuro Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] Alzamend Neuro, Inc. Reports Material Event - Stock Titan
Exit Recap: How sensitive is Alzamend Neuro Inc to inflationEarnings Performance Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Quarterly Recap: Will PAVM outperform during market rallies2026 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
Alzamend initiates phase II trial of AL001 in bipolar disorder By Investing.com - Investing.com South Africa
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - Investing News Network
Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital - marketscreener.com
Alzamend initiates phase II trial of AL001 in bipolar disorder - Investing.com
Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital - TradingView
Alzamend Neuro, Inc. Q3 2026 Financial Results and SEC 10-Q Filing Overview - Minichart
Alzamend Neuro 10-Q: $0.00M Revenue, $(0.58) EPS Q3; $(1.89) EPS YTD - TradingView
Alzamend Neuro (NASDAQ: ALZN) posts $5.9M loss and warns on going concern - Stock Titan
Alzamend Neuro Establishes ATM Equity Offering Agreement - The Globe and Mail
Is Alzamend Neuro Inc stock a hidden gemEarnings Growth Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stockSEC filing - marketscreener.com
Alzamend Neuro Launches $3 Million ATM Equity Program With Ascendiant Capital Markets - TradingView
Alzamend Neuro (ALZN) launches $3.0M at-the-market common stock offering - Stock Titan
Alzamend Neuro Inc expected to post a loss of $1.92 a shareEarnings Preview - TradingView
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
ALZN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALZN Should I Buy - Intellectia AI
Alzamend Neuro (ALZN) to Release Quarterly Earnings on Monday - Defense World
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Expands By 51.2% - Defense World
ALZN Technical Analysis & ETF Price Forecast - Intellectia AI
Reverse split and new equity plan in Alzamend Neuro (ALZN) 2026 proxy - Stock Titan
How risky is Alzamend Neuro Inc. stock now2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - mfd.ru
Can Alzamend Neuro Inc. stock hit record highs againMarket Activity Report & Verified Trade Idea Suggestions - mfd.ru
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alzamend Neuro Inc-Aktie (ALZN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Dec 23 '25 |
Sale |
2.07 |
1,851 |
3,825 |
0 |
| Horne William B. | Director |
Dec 19 '25 |
Sale |
2.12 |
3,333 |
7,059 |
0 |
| McGrath Lynne Fahey | Director |
Oct 23 '25 |
Sale |
2.29 |
30 |
69 |
25 |
| AULT MILTON C III | Director |
Oct 08 '25 |
Sale |
2.44 |
101,394 |
247,158 |
28,657 |
| AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
| AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
| AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
| AULT MILTON C III | Director |
Oct 03 '25 |
Sale |
2.44 |
65,903 |
160,889 |
8,260 |
| AULT MILTON C III | Director |
Oct 01 '25 |
Sale |
2.35 |
36,777 |
86,378 |
94,849 |
| AULT MILTON C III | Director |
Oct 02 '25 |
Sale |
2.39 |
20,686 |
49,522 |
74,163 |
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):